Laurina (Desogestrel, Ethinylestradiol)

Desogestrel, a progestogen, inhibits the hypothalamic‑pituitary‑ovarian axis, preventing the LH and FSH surge needed for ovulation. Ethinylestradiol, an estrogen, provides feedback that stabilises the endometrium and thickens cervical mucus, together reducing the chance of fertilisation and implantation.

The specific dosing regimen for Laurina is determined by the prescribing healthcare professional. Typically, it involves taking one tablet daily at the same time each day, but the exact schedule and duration should follow the prescriber’s instructions.

Laurina is not intended for use during pregnancy; if pregnancy occurs, the product should be discontinued immediately. While limited data exist for breastfeeding, the decision to use Laurina while nursing should be made by a healthcare provider after weighing potential benefits and risks.

To order Laurina, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Laurina contains desogestrel, a third‑generation progestogen, which is associated with a lower incidence of androgenic side effects compared with some older progestins. Its efficacy in preventing pregnancy is comparable to other combined oral contraceptives, while the side‑effect profile may differ slightly based on individual tolerance.

Laurina tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct light, and keep out of reach of children. Do not refrigerate or freeze the tablets.

Laurina is taken orally with a glass of water, preferably at the same time each day. It is usually started on the first day of the menstrual cycle or after a 7‑day hormone‑free interval, as directed by a healthcare professional.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis (stroke or myocardial infarction), severe hypertension, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms suggestive of these conditions.

Laurina is contraindicated in women with a history of thromboembolic disorders, active or past breast cancer, uncontrolled hypertension, severe liver disease, known hypersensitivity to any component, or in those who are pregnant. Women over 35 who smoke should also avoid using this product.